China Medical System Holdings Ltd. Press Release

CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia Apr 01, 2024 20:30 JST More info..

China Medical System (867.HK) 2023 Annual Results: Despite of the Temporary Financial Performance Pressure, Fresh Catalysts Emerged from Successive Innovation Breakthroughs Mar 28, 2024 10:23 JST More info..

China Medical System (00867) Obtained Exclusive License of a First-line Phosphate-lowering Drug Velphoro(R) Feb 04, 2024 09:00 JST More info..

CMS(00867) Joins Hands with Pharmaron to Promote the Singapore Manufacturing Plant Acquisition and CDMO Business in SEA Jan 02, 2024 14:00 JST More info..

China Medical System: 4 Products Have Been Newly Included or Continued to be Included in the NRDL Dec 13, 2023 17:00 JST More info..

China Medical System: NDA for Additional RA Indication of Methotrexate Injection Accepted in China Dec 04, 2023 21:49 JST More info..

China Medical System Gained Exclusive License of an Anti-Ischemic Stroke Class 1 Innovative Drug Aug 24, 2023 20:00 JST More info..

China Medical System Once Again Received MSCI-ESG 'AA' Rating, Leading the Industry in ESG Management
Jul 31, 2023 20:00 JST

Recently, MSCI (Morgan Stanley Capital International), the world's largest index company, announced the latest Environmental, Social, and Governance (ESG) evaluation report for China Medical System Holdings limited ("CMS" or the "Group"), who achieved an "AA" rating and surpassed 75% of global peers with leading ESG management practices.
More info..

China Medical System: The first 'Diazepam Nasal Spray' Approved for Marketing in China Jun 12, 2023 20:00 JST More info..

China Medical System: An Innovative Drug, ILUMETRI 'Tildrakizumab Injection' Approved for Marketing in China
May 30, 2023 23:00 JST

On May 30, China Medical System Holdings Limited ("CMS" or the "Group") announced that on 26 May 2023, the New Drug Application (NDA) of Tildrakizumab Injection under the brand name of ILUMETRI has been approved by the National Medical Products Administration of China (NMPA). ILUMETRI is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
More info..

Gelonghui Reports CMS' Successful Phase III Study of Methylthioninium Chloride Enteric-coated Sustained-release Tablets
Dec 19, 2022 19:00 JST

Gelonghui released a Press Release on "China Medical System Holdings Limited's innovative product Methylthioninium Chloride Enteric-coated Sustained-release Tablets ('the Product') has obtained positive results for its Phase III clinical trial in China."
More info..

China Medical System (867.HK) S&P Global CSA Score Achieved Significant Improvement, Leading the Industry Globally
Nov 18, 2022 20:00 JST

Recently, the S&P Global Corporate Sustainability Assessment (S&P Global CSA) released the 2022 Environmental, Social and Governance (ESG) scores for China Medical System Holdings Limited ("CMS" or the "Group"). CMS achieved a significant improvement with a score of 53 in 2022 from 36 in 2021, surpassing 92% of the global peers and being significantly ahead of the industry average.
More info..

CMS Releases Its 2022 Interim Report, Achieves Sustained Growth with Its Platform Strategy Sep 06, 2022 10:00 JST More info..

Starting its Industrial Investment in Biotech Companies, China Medical System (0867.HK) has Accelerated its Flywheel of Innovation Apr 26, 2021 19:30 JST China Medical System Holdings Limited (0867.HK) ("CMS" or the "Company") has been active in the market this year. More info..

China Medical System (0867.HK) Accelerating Development and Stepping to New Heights, Driven by Innovation
Apr 05, 2021 10:00 JST

As the earning season approaches, once again listed pharmaceutical companies are attracting the attention of the public. Recently, China Medical System Holdings Limited ("CMS" or the "Company") has released its annual results, with both revenue and profit higher than market expectations.
More info..

China Medical System (0867) Ushers in a Revaluation with its Continuous Growth and Synergy between Innovative Business and New Businesses
Mar 30, 2021 20:35 JST

Turnover and net profit increased at the same time, innovative pipeline continued to expand, and the synergy between its businesses became increasingly obvious .....China Medical System Limited (the "Company" or "CMS"), who has just released its annual results, has brought too many surprises to the market.

More info..

China Medical System (0867.HK) Acquires a Dermatology Specialty Company: A Tough Player the Race
Feb 05, 2021 15:33 JST

On February 1, China Medical System (0867.HK) announced that its subsidiary had acquired Luqa Ventures Co., Limited ("Luqa"), a dermatology specialty company. This acquisition expanded its product portfolio to include Luqa's dermatology products and marked the first foray into the medical aesthetic industry for China Medical System.
More info..

China Medical System (00867.HK) MSCI-ESG Rating Upgraded to AA, Reaching Global Level
Dec 21, 2020 19:00 JST

Morgan Stanley Capital International (MSCI) issued a report on December 17 upgrading the ESG (Environmental, Social and Governance) Rating for China Medical System Holdings Limited ("China Medical System"), a well-established, innovation-driven specialty pharma with a focus on sales & marketing in China.
More info..

China Medical System Holdings Limited 2020 Interim Results Announcement
Aug 13, 2020 08:55 JST

China Medical System Holdings Limited ("CMS", or the "Company", SEHK:867), together with its subsidiaries (the "Group"), a well-established, innovation-driven specialty pharma with a focus on sales and marketing in China, announced its unaudited results for the 6 months ended 30 June 2020 ( the "Reporting Period").
More info..

HY Medical AI and You'an Hospital join forces in the battle against NCP
Feb 28, 2020 19:00 JST

Professor Li Hongjun, Chairman of the Professional Committee of Infectious Disease Radiology of the Chinese Medical Association Radiology Branch and Director of the Department of Radiology of You'an Hospital, along with members of the committee worked through the Spring Festival holidays, racing against time to launch the first "Handbook of Medical Imaging Diagnosis of NCP" (English and Chinese Edition).
More info..

The Strength and Potential of China Medical System (867.HK) Reflected in an Untenable Short Selling Attack
Feb 20, 2020 17:04 JST

1. Targeted by a short seller, China Medical System fought back with a strong response and large-scale buyback
More info..

Blue Orca's Short Selling Plan Failed Because the Quality China Medical System (867.HK) Can Withstand Severe Tests
Feb 14, 2020 18:00 JST

While the world attention is on the fight against Coronavirus in China, Blue Orca is concerned about other things at the same time. This time, this foreign short selling agency aimed at a high-quality Chinese pharmaceutical company.
More info..

China Medical System (867.HK) Armed against Short Selling! The Biggest CSO Took Control of Full Industrial Chain Feb 14, 2020 17:25 JST The short-selling company Blue Orca Capital would not have expected that its confrontation with China Medical System Holdings Limited ("China Medical System") actually helped the company. More info..

China Medical System Holdings Limited 2019 Interim Results Announcement
Aug 16, 2019 21:19 JST

China Medical System Holdings Limited ("CMS", or the "Company", SEHK:867), together with its subsidiaries (the "Group"), a well-established, innovation-driven specialty pharma with a focus on sales and marketing in China, announced its unaudited interim results for the 6 months ended 30 June 2019 ( the "Reporting Period").

More info..

With ROE over 20% for a Decade and Stock Price fallen by 60%, is China Medical System (867.HK) Undervalued?
Jul 10, 2019 21:00 JST

If there is an indicator to measure whether the company is good or not from Buffett's perspective, it's believed that most investors will choose ROE (Return on Equity).

More info..